This site is intended for healthcare professionals
Micrograph of bone marrow rendered in pinks and purples

Find disease awareness content and relevant supporting materials

    Learning Zone CME News Trials Guidelines Journals
    Filter results
    Sort by:
    Relevance
    to
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    22/11/19

    FDA approves Calquence to treat chronic lymphocytic leukaemia or small lymphocytic lymphoma.- AstraZeneca.

    AstraZeneca announced that the FDA has approved Calquence (acalabrutinib) for adult patients with chronic lymphocytic leukaemia (CLL) or small lymphocytic...

    Journals
    Journal
    01/11/19

    Chronic lymphocytic leukaemia: from genetics to treatment.

    Chronic lymphocytic leukaemia (CLL), the most frequent type of leukaemia in adults, is a lymphoproliferative disorder that is characterized by the expansion of monoclonal, mature CD5+CD23+ B cells in the peripheral blood...

    • Source: Nature Reviews Clinical Oncology
    Journals
    Journal
    02/04/19

    Chronic lymphocytic leukaemia: the role of T cells in a B cell disease

    Chronic lymphocytic leukaemia (CLL) has long been thought to be an immunosuppressive disease and abnormalities in T-cell subset distribution and function have been observed in many studies. However, the role of T cells (if any)...

    • Source: British Journal of Haematology
    Pair of hands forming a camera square as the lens peers down a long coastal road into the distance
    Insight
    03/02/16

    Launch of new Chronic Lymphocytic Leukaemia CME

    ? A new CME activity titled: ‘Treatment Optimisation in Chronic Lymphocytic Leukaemia’ has been added to the Chronic Lymphocytic Leukaemia...

    Journals
    Journal
    15/02/19

    Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.

    Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi?centre retrospective analysis of 105 R/R CLL patients who received venetoclax...

    • Source: British Journal of Haematology
    Blue test tubes arranged in a line, disappearing into the background
    News
    25/10/24

    Calquence approved in Japan to treat relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma)-AstraZeneca

    AstraZeneca’s Calquence (acalabrutinib), a next-generation, selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in Japan for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) (including small lymphocytic lymphoma [SLL).

    Guidelines
    Guideline
    08/10/25

    2025 BSH Guideline for the treatment of chronic lymphocytic leukaemia

    This 2025 BSH guideline outlines updated treatment strategies for chronic lymphocytic leukaemia (CLL), emphasizing prehabilitation and patient well-being. It details the use of targeted therapies including BCL2 inhibitors, covalent and non-covalent BTK inhibitors, and anti-CD20 monoclonal antibodies, replacing chemoimmunotherapy as standard care.

    • Source: British Society for Haematology (BSH)
    Guidelines
    Guideline
    18/10/20

    Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    These updated ESMO guidelines offer comprehensive recommendations for diagnosing and managing chronic lymphocytic leukaemia (CLL). They emphasize personalized treatment strategies based on genetic and clinical factors, including therapies targeting B-cell receptor pathways and apoptosis mechanisms.

    • Source: European Society for Medical Oncology (ESMO)
    Blue test tubes arranged in a line, disappearing into the background
    Drug news
    23/01/18

    Chronic lymphocytic leukaemia treatment to be removed

    Genmab announces it is removing Arzerra from the chronic lymphocytic leukaemia market outside the US.

    Blue test tubes arranged in a line, disappearing into the background
    News
    12/11/24

    Calquence approved in the EU for the treatment of chronic lymphocytic leukaemia.- AstraZeneca

    AstraZeneca’s Calquence (acalabrutinib), a next-generation selective Bruton’s tyrosine kinase (BTK) inhibitor, has been approved in the European Union (EU) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL), the most common type of leukaemia in adults.

    See more